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Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8)
has been identified as the etiologic agent of Kaposi’s sar-
coma (KS), a multifocal highly vascularized neoplasm
that is the most common malignancy associated with
AIDS. Although highly active antiretroviral therapy has
decreased the incidence of KS, it remains an incurable
tumor for which there is no established treatment. Due
to the vascular nature of KS, an anti-angiogenic thera-
peutic approach is attractive. The KSHV-encoded
G-protein-coupled receptor (vGPCR) is required and
sufficient to initiate angiogenesis and tumorigenesis.
Recent evidence suggests that inhibition of P-TEFb, a
transcriptional elongation factor composed of cyclin
dependent kinase 9 (CDK9) and its regulatory partner
cyclin T, is anti-angiogenic.
We hypothesized that flavopiridol, a novel inhibitor of
CDK9, would inhibit vGPCR-induced angiogenesis by
downregulating expression of angiogenic growth factors
and/or Bcl-2. To test this hypothesis, in vitro and in
vivo angiogenesis assays were carried out using primary
human umbilical vein endothelial cells (HUVECs) trans-
duced with either a control or a vGPCR-expressing ret-
roviral vector and then treated with flavopiridol. Our
results show that CDK9 activity is increased in vGPCR-
expressing HUVECs and that pretreatment with 50 nM
flavopiridol inhibited vGPCR-induced migration and
capillary tubule formation. These results correlated with
a significant decrease in expression of genes encoding
the angiogenic factors VEGF-A and VEGF-C and the
pro-survival factor Bcl-2. Initial studies to determine the
molecular mechanisms by which CDK9 affects angio-
genesis demonstrated that HUVECs treated with bFGF
and VEGF had increased CDK9 activity as well as
increased expression of the major isoform of Cdk942
and cyclin T. Although Cdk9 was described in the litera-
ture as a general transcription factor, we have observed
that inhibition of CDK9 by flavopiridol decreased the
expression of Bcl-2 but not p21 in HUVEC. Together
these results suggest that CDK9 plays a role in mediat-
ing transcriptional regulation of vGPCR responsive
genes and implicate CDK9 as a potential target to
reduce vGPCR-enhanced endothelial cell survival, angio-
genesis, and tumorigenesis. Experiments are currently
under way to determine whether CDK9 is directly acti-
vated upon vGPCR expression and whether inhibition of
CDK9 activity suppresses KSHV-enhanced angiogenesis
and tumorigenesis in vivo.
Acknowledgements
This article has been published as part of Infectious Agents and Cancer
Volume 5 Supplement 1, 2010: Proceedings of the 12
th International
Conference on Malignancies in AIDS and Other Acquired
Immunodeficiencies (ICMAOI).The full contents of the supplement are
available online at http://www.biomedcentral.com/1750-9378/5?issue=S1.
Author details
1Department of Biology, Xavier University of Louisiana, New Orleans, LA,
USA.
2Department of Microbiology and Immunology, Tulane University
School of Medicine, New Orleans, LA, USA.
3Program in Lung Biology,
Department of Pathology, Tulane University School of Medicine, New
* Correspondence: hmcferri@xula.edu
1Department of Biology, Xavier University of Louisiana, New Orleans, LA, USA
Full list of author information is available at the end of the article
McFerrin et al. Infectious Agents and Cancer 2010, 5(Suppl 1):A75
http://www.infectagentscancer.com/content/5/S1/A75
© 2010 McFerrin et al; licensee BioMed Central Ltd.Orleans, LA, USA.
4NCIRD/DVD/MMRHLB/Herpesvirus Team, Centers for
Disease Control and Prevention, Atlanta, GA, USA.
Published: 11 October 2010
doi:10.1186/1750-9378-5-S1-A75
Cite this article as: McFerrin et al.: The angiogenic properties of Kaposi’s
sarcoma-associated herpesvirus encoded G-protein coupled receptor
are reduced by flavopiridol, an inhibitor of cyclin-dependent kinase 9.
Infectious Agents and Cancer 2010 5(Suppl 1):A75.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
McFerrin et al. Infectious Agents and Cancer 2010, 5(Suppl 1):A75
http://www.infectagentscancer.com/content/5/S1/A75
Page 2 of 2